{"version":"1.0","type":"rich","width":"560px","height":"140px","title":"Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) Trial","url":"https:\/\/www.myelomasociety.org\/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial\/","author_name":"IMSound","author_url":"https:\/\/www.myelomasociety.org","thumbnail_url":"https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/07\/IMSound-Logo-only-v2.png","html":"<iframe width=\"560px\" height=\"140px\" src=\"https:\/\/www.myelomasociety.org\/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial\/?standalonePlayer\"><\/iframe>"}